Rothschild & CO Asset Management Us Inc. Nektar Therapeutics Transaction History

Rothschild & CO Asset Management Us Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 13, 2018	SELL	$46.46 - $68.49 $6.6 Million - $9.73 Million	-142,133 Closed	0 $0
Q2 2018 Aug 07, 2018	SELL	$46.25 - $104.45 $12.5 Million - $28.3 Million	-271,014 Reduced 65.6%	142,133 $6.94 Million
Q1 2018 May 08, 2018	SELL	$57.4 - $108.44 $12.3 Million - $23.2 Million	-214,132 Reduced 34.14%	413,147 $43.9 Million
Q4 2017 Feb 12, 2018	SELL	$23.02 - $60.5 $12.8 Million - $33.6 Million	-555,143 Reduced 46.95%	627,279 $37.5 Million
Q3 2017 Nov 08, 2017	BUY	$17.79 - $24.0 $21 Million - $28.4 Million	1,182,422	1,182,422 $28.4 Million

147

139M

32.6K

14.1K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $201M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Rothschild & CO Asset Management Us Inc., based on Form 13F filings with the SEC.

Stay updated on Rothschild & CO Asset Management Us Inc. with notifications on news.